biotech.today

Details

  • ●Modalities: small molecules (repurposed)
  • ●Therapeutic areas: rare disease
  • ●Key targets:
  • ●Indications: Undisclosed
  • ●Funding: $56M

Partners & investors

  • Atomico· Investor

Key considerations

  • ●AI tools in use: Healnet Platform
  • ●$56M Series B (2020)
  • ●Atomico backing

Pipeline

  • Phase 21
Get live updates on Healx’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Tim Guilliams

Co-Founder & CEO

rare-diseaseai-drug-repurposing
Visit website →LinkedIn →